EE200300419A - R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina - Google Patents

R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina

Info

Publication number
EE200300419A
EE200300419A EEP200300419A EEP200300419A EE200300419A EE 200300419 A EE200300419 A EE 200300419A EE P200300419 A EEP200300419 A EE P200300419A EE P200300419 A EEP200300419 A EE P200300419A EE 200300419 A EE200300419 A EE 200300419A
Authority
EE
Estonia
Prior art keywords
methyl
aminopropane
norepinephrine
hydroxyphenyl
oxy
Prior art date
Application number
EEP200300419A
Other languages
English (en)
Estonian (et)
Inventor
Louis Mattiuz Edward
Sauer John-Michael
Joe Wheeler William
Taiwai Wong David
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300419(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of EE200300419A publication Critical patent/EE200300419A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200300419A 2001-03-06 2002-02-20 R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina EE200300419A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06
PCT/US2002/003385 WO2002070457A1 (en) 2001-03-06 2002-02-20 Inhibitor of monoamine uptake

Publications (1)

Publication Number Publication Date
EE200300419A true EE200300419A (et) 2004-02-16

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300419A EE200300419A (et) 2001-03-06 2002-02-20 R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina

Country Status (35)

Country Link
US (2) US20040082666A1 (https=)
EP (1) EP1379492B1 (https=)
JP (1) JP2004525912A (https=)
KR (1) KR20030092012A (https=)
CN (1) CN1229331C (https=)
AP (1) AP2003002855A0 (https=)
AT (2) AT414238B (https=)
AU (1) AU2002245385B2 (https=)
BR (1) BR0207716A (https=)
CA (1) CA2440161A1 (https=)
CH (1) CH695982A5 (https=)
CZ (1) CZ20032380A3 (https=)
DE (1) DE60226715D1 (https=)
DK (1) DK200301267A (https=)
EA (1) EA005768B1 (https=)
EC (1) ECSP034760A (https=)
EE (1) EE200300419A (https=)
ES (2) ES2201942B2 (https=)
FI (1) FI20031191L (https=)
GB (1) GB2389851B (https=)
HR (1) HRP20030710A2 (https=)
HU (1) HUP0303341A3 (https=)
IL (1) IL157779A0 (https=)
LT (1) LT5143B (https=)
LU (1) LU91038B1 (https=)
LV (1) LV13119B (https=)
NO (1) NO20033921L (https=)
NZ (1) NZ527431A (https=)
OA (1) OA12494A (https=)
PL (1) PL363840A1 (https=)
SE (1) SE526598C2 (https=)
SK (1) SK10632003A3 (https=)
TR (1) TR200705146T1 (https=)
WO (1) WO2002070457A1 (https=)
ZA (1) ZA200306882B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695982A5 (de) * 2001-03-06 2006-11-15 Lilly Co Eli Inhibitor der Monaminaufnahme.
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
EP1729754B1 (en) * 2003-12-12 2008-07-02 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
WO2011027359A2 (en) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
WO2020091862A1 (en) * 2018-10-31 2020-05-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA1327795C (en) * 1987-08-14 1994-03-15 Jules Freedman Antidepressants which are aryloxy inadanamines
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
AU3219800A (en) 1999-03-29 2000-10-16 Eli Lilly And Company Stereospecific method for preparing tomoxetine and intermediates thereof
CA2362185C (en) 1999-04-09 2009-06-02 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
BR0115301A (pt) * 2000-11-15 2004-12-14 Lilly Co Eli Uso de um inibidor seletivo da recaptação de norepinefrina
CH695982A5 (de) * 2001-03-06 2006-11-15 Lilly Co Eli Inhibitor der Monaminaufnahme.

Also Published As

Publication number Publication date
BR0207716A (pt) 2004-03-23
EP1379492B1 (en) 2008-05-21
HUP0303341A3 (en) 2007-03-28
FI20031191A7 (fi) 2003-08-25
ECSP034760A (es) 2003-10-28
WO2002070457A8 (en) 2004-06-03
ATA90422002A (de) 2006-01-15
ATE396170T1 (de) 2008-06-15
CN1494526A (zh) 2004-05-05
SE0302361L (sv) 2003-09-03
SK10632003A3 (sk) 2004-06-08
DE60226715D1 (de) 2008-07-03
CH695982A5 (de) 2006-11-15
HRP20030710A2 (en) 2004-08-31
GB0323169D0 (en) 2003-11-05
ZA200306882B (en) 2004-12-03
NZ527431A (en) 2005-05-27
SE526598C2 (sv) 2005-10-18
FI20031191L (fi) 2003-08-25
US20040082666A1 (en) 2004-04-29
AU2002245385B2 (en) 2007-01-18
LT5143B (lt) 2004-06-25
EP1379492A1 (en) 2004-01-14
EA005768B1 (ru) 2005-06-30
PL363840A1 (pl) 2004-11-29
TR200705146T1 (tr) 2008-02-21
SE0302361D0 (sv) 2003-09-03
DK200301267A (da) 2003-11-06
CN1229331C (zh) 2005-11-30
JP2004525912A (ja) 2004-08-26
LT2003075A (en) 2004-03-25
CA2440161A1 (en) 2002-09-12
LU91038B1 (fr) 2003-09-11
ES2201942B2 (es) 2004-12-16
AT414238B (de) 2006-10-15
ES2305221T3 (es) 2008-11-01
WO2002070457A1 (en) 2002-09-12
GB2389851A (en) 2003-12-24
OA12494A (en) 2006-05-24
GB2389851B (en) 2005-05-25
KR20030092012A (ko) 2003-12-03
IL157779A0 (en) 2004-03-28
ES2201942A1 (es) 2004-03-16
NO20033921L (no) 2003-11-05
CZ20032380A3 (en) 2004-03-17
AP2003002855A0 (en) 2003-08-20
US7384983B2 (en) 2008-06-10
NO20033921D0 (no) 2003-09-04
LV13119B (en) 2004-06-20
EA200300978A1 (ru) 2004-02-26
HUP0303341A2 (hu) 2004-01-28
US20050209341A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60213592D1 (de) Flüssige pharmazeutische zusammensetzung
NO20033384L (no) Farmasoytisk formulering
EE05378B1 (et) LahustuvaÁCTLA4ÁsulandmolekuliÁkasutamineÁravimkoostiseÁvalmistamiseks
FI20011478L (fi) Farmaseuttinen koostumus
NO20025450L (no) Ny farmasöytisk sammensetning
ATE355271T1 (de) Pharmazeutische zusammensetzung
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
NO20035627D0 (no) Farmasöytisk formulering
NO20040254L (no) Farmasoytiske sammensetninger som inneholder terbinafin og anvendelse derav
FI20022128A0 (fi) Farmaseuttinen koostumus
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
EE200300419A (et) R-(-)-N-metüül-3-[(2-metüül-4-hüdroksüfenüül)oksü]-3-fenüül-1-aminopropaan, seda sisaldav ravimpreparaat ning ühendi kasutamine norepinefriini ja serotoniini sissehaarde inhibiitorina
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE366128T1 (de) Pharmazeutische zusammensetzung
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DK1313481T3 (da) Farmaceutisk sammensætning, som omfatter kondenserede indolforbindelser
NO20041236L (no) Farmasoytisk formulering
SE0102069D0 (sv) Pharmaceutical formulation
SE0102572D0 (sv) Pharmaceutical formulation
SE0101326D0 (sv) Pharmaceutical formulation